Literature DB >> 6095093

Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones.

J Bradwejn, C de Montigny.   

Abstract

Cholecystokinin (CCK) is a neuropeptide present in the mammalian central nervous system (CNS). In all species studied so far, the highest concentrations of this neuropeptide have been found in the cerebral cortex, the amygdala and the hippocampus. Five molecular forms of CCK having 39, 33, 13, 8 and 4 amino acid residues have been identified in the CNS, the sulphated octapeptide (CCK8) being the most abundant form detected. Specific CCK binding sites have been demonstrated in the rat, guinea pig and human brain. CCK8, applied by microiontophoresis to deep cortical neurones and hippocampal pyramidal neurones, has a powerful excitatory effect, whereas the non-sulphated CCK octapeptide has no such effect on these neurones. Low doses of benzodiazepines depress the spontaneous activity of hippocampal pyramidal neurones. We report here that benzodiazepines at very low doses antagonize selectively the CCK8-induced activation of rat hippocampal pyramidal neurones. This antagonistic action might be involved in the anxiolytic effect of these drugs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095093     DOI: 10.1038/312363a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  23 in total

1.  Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.

Authors:  B E Evans; M G Bock; K E Rittle; R M DiPardo; W L Whitter; D F Veber; P S Anderson; R M Freidinger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

2.  Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment.

Authors:  J Harro; M Põld; E Vasar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990 Jan-Feb       Impact factor: 3.000

3.  Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test.

Authors:  Sirli Raud; Jürgen Innos; Urho Abramov; Ain Reimets; Sulev Kõks; Andres Soosaar; Toshimitsu Matsui; Eero Vasar
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

4.  The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.

Authors:  P Chopin; M Briley
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Effects of the CCKB antagonist L-365, 260 on benzodiazepine withdrawal-induced hypophagia in rats.

Authors:  A J Goudie; M J Leathley
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

6.  Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse.

Authors:  Qian Chen; Akira Nakajima; Corbin Meacham; Ya-Ping Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

Review 7.  Generalised anxiety disorder: treatment options.

Authors:  John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens.

Authors:  P Paudice; M Raiteri
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

9.  Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caerulein.

Authors:  E Vasar; E Peuranen; J Harro; A Lang; L Oreland; P T Männistö
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

10.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.